Extramembranous glomerulonephritis
Conditions
Brief summary
Intraindividual variation in anti-PLA2R1 antibody titer (ELISA titer in RU/mL), after 6 months of IFNα (Pegasys®) treatment compared to pre-treatment antibody titer
Detailed description
Intraindividual variation in proteinuria and albumin levels under IFNα (Pegasys®) treatment and stable symptomatic treatment, Intraindividual variation in cytokine profile (assay of 9 cytokines: IL-12p70; IL-17A; IL-4; IL-5; IL-1β; IL-10; IFNα; IL-6 and IFNγ) before and after 6 months of personalized treatment with IFNα (Pegasys®), Clinical and Biological Tolerance of IFNα Therapy (Pegasys®), Description of an effective IFNα (Pegasys®) regimen (one or two monthly doses) to induce an IL-17A level below 73 pg/ml
Interventions
Sponsors
Centre Hospitalier Universitaire De Nice
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intraindividual variation in anti-PLA2R1 antibody titer (ELISA titer in RU/mL), after 6 months of IFNα (Pegasys®) treatment compared to pre-treatment antibody titer | — |
Secondary
| Measure | Time frame |
|---|---|
| Intraindividual variation in proteinuria and albumin levels under IFNα (Pegasys®) treatment and stable symptomatic treatment, Intraindividual variation in cytokine profile (assay of 9 cytokines: IL-12p70; IL-17A; IL-4; IL-5; IL-1β; IL-10; IFNα; IL-6 and IFNγ) before and after 6 months of personalized treatment with IFNα (Pegasys®), Clinical and Biological Tolerance of IFNα Therapy (Pegasys®), Description of an effective IFNα (Pegasys®) regimen (one or two monthly doses) to induce an IL-17A level below 73 pg/ml | — |
Countries
France
Outcome results
None listed